Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals.
Slavin S, Aker M, Shapira MY, Panigrahi S, Gabriel C, Or R.
Transfus Apher Sci. 2002 Oct;27(2):159-66. doi: 10.1016/s1473-0502(02)00038-1.
Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S.
Int J Hematol. 2002 Aug;76 Suppl 1:176-83. doi: 10.1007/BF03165241.
Non-myeloablative allogeneic hematopoietic stem cell transplantation.
Shelburne N, Bevans M.
Semin Oncol Nurs. 2009 May;25(2):120-8. doi: 10.1016/j.soncn.2009.03.006.
Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation.
Slavin S.
Int J Hematol. 2002 Aug;76 Suppl 1:172-5. doi: 10.1007/BF03165240.
Critical review on non-myeloablative stem cell transplantation (NST).
Anagnostopoulos A, Giralt S.
Crit Rev Oncol Hematol. 2002 Nov;44(2):175-90. doi: 10.1016/s1040-8428(01)00226-8.
Autologous stem-cell transplantation and purging.
Löwenberg B, Voogt P.
J Clin Oncol. 1996 Aug;14(8):2194-6. doi: 10.1200/JCO.1996.14.8.2194.
Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
Sweetenham JW.
Bone Marrow Transplant. 2001 Nov;28(9):813-20. doi: 10.1038/sj.bmt.1703255.
Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
Pettengell R.
Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S1-4. doi: 10.1038/sj.bmt.1703294.
Rituximab: enhancing stem cell transplantation in mantle cell lymphoma.
Gianni AM, Cortelazzo S, Magni M, Martelli M; Michelangelo Cooperative.
Bone Marrow Transplant. 2002 Feb;29 Suppl 1:S10-3. doi: 10.1038/sj.bmt.1703296.
[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor].
Endo M, Tanosaki R.
Gan To Kagaku Ryoho. 1995 Oct;22(12):1762-70.
